Replies to post #240763 on Biotech Values

[DewDiligence]

Re: ABUS AB-836 data

For the 100mg cohort, ABUS said median reduction of 3.1 logs at 28 days.

The reported AB-836 cohort had n=4!! Also, ABUS didn’t say what, specifically, was reduced by 3.1 logs in this cohort—was it HBV DNA or HBV RNA? ABUS also didn’t give the mean baseline readings (DNA, RNA) for the patients in the n=4 cohort.

All told, it’s too early to say that AB-836 is comparable to EDP-514—or to any other HBV core inhibitor. ABUS’ 12/1/21 PR contained so little actual data that I’m certain the timing of the release was intended to boost the share price for ATM selling on the day of the big bounce from the patent ruling (#msg-166969906).

p.s. Not sure what you’re referring to in ABUS’ slide set.